ATTRibute-CM Is a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy

About the Attribute-cm global PHASE 3 trial

An ongoing Phase 3 trial of AG10 in patients with symptomatic ATTR cardiomyopathy (ATTR-CM) is now enrolling ( Identifier: NCT03860935).

trial design trial design


  • Eligible patients will be randomized in a 2:1 ratio and receive either AG10 800 mg or matching placebo orally, twice daily
  • Screening and randomization will be followed by a total of 30 months of blinded, placebo-controlled treatment


  • At the end of 12 months of treatment (Part A), efficacy of AG10 will be assessed through analysis of the functional Six-Minute Walk Test (6MWT) and health-related quality of life (QoL) (as measured by the heart failure (HF)-specific instrument Kansas City Cardiomyopathy Questionnaire [KCCQ]) endpoints
  • At the end of 30 months of treatment (Part B), efficacy of AG10 will be further assessed through analysis of all-cause mortality and cardiovascular (CV)-related hospitalization. NOTE: During Part B, as local standard of care evolves, concomitant use of approved, indicated therapies may be allowed


  • All subjects who complete 30 months of blinded trial therapy and the final assessments of the double-blind treatment period may be eligible to participate in an open-label extension trial of long-term AG10 treatment

Eligibility Criteria

Key Inclusion Criteria*:

  • Male or female between the ages of ≥18 and ≤90 (inclusive)
  • Established diagnosis of ATTR-CM with either wild-type transthyretin (TTR) or variant TTR genotype
  • History of heart failure evidenced by one of the following:
    • at least one prior hospitalization for heart failure clinical evidence of heart failure without prior heart failure hospitalization manifested by signs or symptoms of volume overload
    • elevated intracardiac pressures
    • heart failure symptoms that required or require ongoing treatment with a diuretic
  • New York Heart Association (NYHA) Class I-III symptoms due to ATTR-CM
  • Completed ≥150 m on the 6MWT on two consecutive tests prior to randomization

Key Exclusion Criteria*:

  • Acute myocardial infarction, acute coronary syndrome, coronary revascularization, or stroke within 90 days prior to screening
  • Likely to undergo heart transplantation within a year of screening
  • Confirmed diagnosis of primary (light-chain) amyloidosis
  • Current treatment with marketed drug products and other investigational agents for the treatment of ATTR-CM

* Additional inclusion and exclusion criteria apply. Patients must meet all eligibility criteria to be considered for the clinical research trial. For more information, search NCT03860935 on


Learn more at

mail icon

Contact us today at to learn more about the ATTRibute-CM trial.